8-K: Lifecore Biomedical Reports FY25 Results, Shifts Fiscal Year

Lifecore Biomedical reported fiscal year 2025 revenue of $128.9 million, meeting full-year guidance, and announced a shift to a calendar year fiscal end, alongside new program signings and operational efficiencies.

Summary

• Fiscal Year 2025 (ended May 25, 2025) revenue was $128.9 million, meeting full-year guidance, representing a 0.5% increase from $128.3 million in the prior year.
• Full-year fiscal 2025 net loss was $38.7 million ($1.27 loss per diluted share), compared to a net income of $12.0 million ($0.33 income per diluted share) in the prior year.
• Full-year fiscal 2025 Adjusted EBITDA was $19.5 million, a decrease of $0.7 million from $20.2 million in the prior year.
• Fourth Quarter Fiscal 2025 (ended May 25, 2025) revenues were $36.4 million, a 4% decrease compared to $37.9 million in the comparable prior year period.
• Fourth quarter fiscal 2025 net loss was $1.1 million ($0.06 loss per diluted share), significantly improved from a net loss of $7.1 million ($0.19 loss per diluted share) in the prior year period.
• Fourth quarter fiscal 2025 Adjusted EBITDA was $9.1 million, a decrease of $1.3 million compared to $10.4 million in the prior year period.
• Signed nine new programs with new customers during fiscal 2025, expanding into modalities beyond traditional ophthalmic therapeutics.
• Subsequent to quarter end, signed several new customer agreements, including a late-stage product with a leading developer of GLP-1 therapeutics for obesity and a Phase 2 dermatology program.
• Implemented organizational restructuring, right-sized headcount, and reduced expenses as a percentage of revenue, while increasing revenue per direct labor employee.
• Planned launch of a new enterprise resource planning (ERP) system in the first quarter of calendar year 2026, expected to enable further operational efficiencies and cost savings.
• Moving fiscal year end to align with the calendar year, effective for the December 31, 2025 calendar period, to report in a timely manner with peer companies and stakeholders.

Sentiment

Score: 6

Explanation: While the company reported a significant net loss for the full fiscal year and a decline in Q4 revenue and gross profit, it met its full-year revenue guidance. The strategic initiatives, including new customer programs, diversification into new therapeutic areas (GLP-1, dermatology), operational efficiencies, and the planned ERP system, indicate positive momentum and future growth potential. The shift to a calendar fiscal year also improves transparency and comparability. However, the substantial net loss and increased SG&A and interest expenses for the full year are notable negatives.

Positives

• Met full-year fiscal 2025 revenue guidance of $128.9 million.
• Signed nine new programs with new customers in fiscal 2025, reflecting growth into modalities beyond ophthalmic therapeutics.
• Secured new customer agreements subsequent to quarter end, including a late-stage GLP-1 therapeutic product and a Phase 2 dermatology program.
• Improved operational efficiency and productivity, leading to reduced operational expenses and increased revenue per direct labor employee.
• Reduced Selling, General and Administrative (SG&A) expenses by $3.2 million in Q4 2025 due to focused efforts to reduce operational expenses and new leadership.
• Net loss significantly narrowed in Q4 2025 to $1.1 million from $7.1 million in the prior year period.
• Hyaluronic acid (HA) manufacturing revenues increased by $4.1 million in Q4 2025 and $7.1 million in FY2025 due to increased demand from a largest customer's supply chain initiatives.
• Established a performance-driven culture and reinforced commitment to quality under new leadership.

Negatives

• Fourth quarter 2025 revenue decreased by 4% to $36.4 million, primarily due to a $5.6 million decrease in CDMO revenues.
• CDMO revenue decline in Q4 was primarily impacted by $4.4 million of lower development revenue due to completion of a discrete project and timing of customer project lifecycles.
• Gross profit decreased by $3.3 million in Q4 2025 to $14.0 million, primarily due to a $6.0 million decrease in CDMO gross profit.
• Full-year fiscal 2025 net loss was $38.7 million, a significant decline from $12.0 million net income in the prior year, partly due to a $7.7 million loss on the sale or disposal of assets and a less favorable debt derivative adjustment.
• Full-year fiscal 2025 gross profit decreased by $1.6 million to $40.3 million, primarily due to a $5.9 million decrease in CDMO gross profit.
• Full-year fiscal 2025 SG&A expenses increased by $3.5 million to $44.0 million, primarily due to a $3.7 million increase in non-cash stock-based compensation.
• Full-year fiscal 2025 interest expense increased by $3.7 million to $21.8 million, primarily from Alcon term loans with accumulating paid-in-kind interest and amortization of debt discount.

Risks

• Timing and amount of future expenses, revenue, Adjusted EBITDA, cash flow, and capital requirements.
• Timing and availability of and the need for additional financing.
• Ability to maintain or expand relationships with current customers, including the impact of changes in consumer demand for manufactured products.
• Ability to grow and diversify business with new customers, including the potential loss of development customers if they do not receive required funding or regulatory approvals.
• Ability to comply with covenants under credit agreements and to pay required interest and principal payments when due.
• Ability to raise additional capital for ongoing needs, including through equity financing, debt financing, collaborations, strategic alliances, or licensing arrangements.
• Impact of macroeconomic events or circumstances on operations and financial performance, including inflation, tariffs, interest rates, social unrest, and global instability.
• Performance of third-party suppliers.
• Pharmaceutical industry market forces that may impact customer success and continued demand for products.
• Ability to recruit or retain key scientific, technical, business development, and management personnel and executive officers.
• Ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice (cGMP).
• Outcome and cost of existing and any new litigation or regulatory proceedings.

Future Outlook

Management expects revenue for the seven-month transition period from May 26 to December 31, 2025, to be approximately $74 million to $76 million. Net loss is projected to range from $19.8 million to $17.8 million, with Adjusted EBITDA expected between $12 million and $14 million. The company maintains its mid-term outlook of delivering a 12%+ revenue CAGR and expanding adjusted EBITDA margins to more than 25%.

Management Comments

• "Driven by our new and highly experienced leadership team, we restructured our organization and implemented numerous efficiencies across the company during fiscal 2025. We right-sized our headcount and reduced expenses as a percentage of revenue, all while increasing our revenue per direct labor employee."
• "Our strengthened organization advanced our growth strategies by executing expansion plans with an existing customer in support of a significant increase in projected demand. We also progressed our late-stage pipeline toward commercialization and added multiple new customers."
• "We are pleased with our business development efforts during fiscal 2025 and are highly encouraged by the progress of our talented new business development team and our growing momentum at fiscal year-end. This momentum, combined with solid progress across our other growth strategies, positions us well to achieve our goal of delivering a 12%+ revenue CAGR and expanding adjusted EBITDA* margins to more than 25% over the mid-term."

Industry Context

Lifecore Biomedical operates as a CDMO, a sector experiencing growth driven by pharmaceutical and biotechnology companies outsourcing drug development and manufacturing. The company's expansion into modalities beyond ophthalmic therapeutics, such as GLP-1 and dermatology, reflects a strategic move to diversify its service offerings and tap into high-growth therapeutic areas, aligning with broader industry trends of specialized CDMO services for complex formulations and biologics. The shift to a calendar fiscal year aligns with industry peers, enhancing comparability for investors and stakeholders.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards.
• The company's stated mid-term goal of a 12%+ revenue CAGR and over 25% Adjusted EBITDA margins suggests an ambition to achieve performance metrics competitive within the CDMO sector, where strong growth and profitability are key indicators of success.
• The expansion into GLP-1 therapeutics, a rapidly growing market, positions Lifecore to potentially capitalize on significant industry demand, similar to how other CDMOs are expanding capabilities to support novel drug classes.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions "the outcome and cost of existing and any new litigation or regulatory proceedings" as a risk factor.
• It also refers to "legal expenses" related to legacy matters and stockholder activist settlement costs in SG&A.

Related Party Transactions

• Accounts receivable, related party: $13,537 thousand (May 25, 2025) and $10,810 thousand (May 26, 2024).
• Revenues, related party: $16,676 thousand (Q4 2025) and $14,740 thousand (Q4 2024).
• Revenues, related party: $56,539 thousand (FY2025) and $50,587 thousand (FY2024).
• Interest expense, related party: $5,123 thousand (Q4 2025) and $4,908 thousand (Q4 2024).
• Interest expense, related party: $18,879 thousand (FY2025) and $14,662 thousand (FY2024).
• Debt, net of current portion, related party: $121,198 thousand (May 25, 2025) and $100,819 thousand (May 26, 2024).
• Debt derivative liability, related party: $24,991 thousand (May 25, 2025) and $25,400 thousand (May 26, 2024).
• The Alcon term loans are mentioned as related party debt.

Stakeholder Impact

• Shareholders: Impacted by the full-year net loss, but also by strategic growth initiatives, potential future profitability, and improved transparency from the fiscal year change.
• Employees: Affected by "right-sized headcount" (reductions) but also by efforts to improve efficiency, productivity, and foster a "performance-driven culture."
• Customers: Benefiting from a "strengthened organization," "expansion plans," and a "progressed late-stage pipeline," with new programs signed.
• Creditors: Affected by increased interest expense on Alcon term loans and the potential future need for additional financing.

Next Steps

• Host a conference call on August 7, 2025, at 4:30 p.m. ET to discuss financial results.
• Provide additional updates on the fiscal year transition in the coming months.
• Launch a new enterprise resource planning (ERP) system in Q1 2026 (calendar year).
• Continue to progress late-stage pipeline toward commercialization.
• Execute expansion plans with an existing customer for projected demand increase.

Key Dates

Recommendation

Lifecore Biomedical's fiscal year 2025 results present a mixed picture. While the company successfully met its revenue guidance and demonstrated strong strategic progress with new customer acquisitions and diversification into high-growth therapeutic areas like GLP-1, the significant full-year net loss and increased expenses are concerning. Operational efficiencies and the planned ERP system are positive steps for future profitability. The shift to a calendar fiscal year enhances transparency. Given the current financial headwinds (net loss, increased interest expense) balanced by clear strategic growth initiatives and operational improvements, a 'hold' recommendation is appropriate. Investors should monitor the execution of new programs, the impact of the ERP system, and progress towards mid-term financial targets before considering a stronger position.

Keywords

Lifecore Biomedical, LFCR, CDMO, Contract Development and Manufacturing, Hyaluronic Acid, HA, Pharmaceutical, Biotech, Financial Results, Earnings, Fiscal Year 2025, Q4 2025, SEC Filing, 8-K, Corporate Update, GLP-1, Dermatology, Ophthalmic Therapeutics, ERP System